Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Collegium Pharmaceutical, Inc. filings document regulatory disclosures for a commercial biopharmaceutical company with ADHD and pain-management medicines. Form 8-K reports cover operating results, earnings presentations, Regulation FD materials, guidance, material agreements, capital-structure matters and clinical or regulatory disclosures tied to the company's product portfolio.
Proxy materials describe shareholder voting matters, board composition, director nominations, board succession, executive compensation and governance practices. The filing record also captures product-related risk disclosures and formal public-company reporting for Collegium's Nasdaq-listed common stock.
COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of Common Stock at $16.49 per share. These options were fully vested and exercisable. After the transaction, Santini directly holds 112,483 shares of Common Stock, and the exercised option covering 8,700 shares is fully used.
Collegium Pharmaceutical director John Gordon Freund reported a small open-market sale of common stock. On May 18, 2026, he sold 20 shares of Collegium Pharmaceutical common stock at $34.05 per share in a direct transaction.
After this sale, he directly held 83,952 common shares. The filing also shows indirect interests in entities holding 8,625 shares through Skyline Venture Management V, LLC and 23,129 shares through John Freund Family Partnership IV, L.P., with beneficial ownership disclaimed except for his proportionate pecuniary interest.
Lurker Nancy reported acquisition or exercise transactions in this Form 4 filing.
Collegium Pharmaceutical director Nancy Lurker received a grant of 8,741 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 annual shareholder meeting, if she continues serving as a director.
After this equity award, Lurker’s direct holdings total 26,758 shares of common stock. The RSUs will be settled in shares on vesting or, if she so elects, upon the earlier of her board service ending, her death or disability, or a change in control of Collegium Pharmaceutical.
Paya Carlos V reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL, INC director Carlos V. Paya reported a compensation-related equity grant. He received 8,741 restricted stock units (RSUs), each representing one share of common stock, increasing his direct holdings to 28,323 shares after the award.
The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, subject to his continued board service. Settlement will be in shares of common stock on the vesting date or, if elected, on the earlier of the end of his board service, death or disability, or a change in control of the company.
Collegium Pharmaceutical director John Gordon Freund reported several equity transactions. On May 15, 2026, he sold 4,127 shares of common stock in an open-market trade at $34.54 per share and exercised stock options to acquire 8,700 shares at $16.49 per share. Following these transactions, he directly holds 83,972 common shares. On May 14, 2026, he also received a grant of 8,741 restricted stock units (RSUs), which vest on the earlier of May 14, 2027 or the company’s 2027 annual meeting, subject to continued board service. In addition, filings show indirect holdings of 23,129 shares through John Freund Family Partnership IV, L.P. and 8,625 shares through Skyline Venture Management V, LLC, where he shares voting and investment power and disclaims beneficial ownership beyond his proportionate pecuniary interest.
Glancy Donovan Michael reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL, INC director Michael Glancy was granted 17,482 restricted stock units on May 14, 2026 at no cash cost. Two equal tranches of 8,741 RSUs are scheduled to vest around May 14, 2027, contingent on continued board service, leaving him with 17,482 shares reported following the grant.
BOHLIN GAREN G reported acquisition or exercise transactions in this Form 4 filing.
Collegium Pharmaceutical director Garen G. Bohlin received an equity award in the form of restricted stock units. The grant covers 8,741 RSUs, each representing one share of common stock, increasing his direct holdings to 71,000 shares. The RSUs vest on the earlier of May 14, 2027 or the company’s 2027 Annual Meeting of Shareholders, contingent on continued board service. Settlement will occur in shares of common stock at vesting or, if elected, upon the end of board service, death, disability, or a change in control.
Balice-Gordon Rita J. reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL director Rita J. Balice-Gordon received an equity grant in the form of restricted stock units (RSUs). The award covers 8,741 RSUs, each representing one share of common stock, and increases her direct holdings to 61,370 shares after the transaction.
The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, as long as she continues serving as a director. Settlement occurs in shares on that vesting date or, if she elects, at the end of her board service, upon death or disability, or upon a change in control of the company.
SANTINI GINO reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL director Gino Santini received an equity award of 8,741 restricted stock units (RSUs) of common stock on May 14, 2026. Each RSU represents one share of common stock at no purchase price.
The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, if he continues serving as a director. Settlement can occur then or, if he elects, at the end of his board service, upon death or disability, or upon a change in control. Following this grant, he directly holds 103,783 shares.
COLL submitted a Form 144 notice reporting securities to be sold and recent dispositions. The filing lists 30 shares of Common stock tied to a Restricted Stock Vesting event dated 05/24/2019 and shows 4,127 shares sold on 05/15/2026 for $142,546.99. The broker-dealer listed is Fidelity Brokerage Services LLC with an indicated date of 05/18/2026.